This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Patient Registry Study of Berinert® in Normal Clinical Practice

This study has been completed.
Chiltern International Inc.
Information provided by (Responsible Party):
CSL Behring Identifier:
First received: April 12, 2010
Last updated: June 5, 2014
Last verified: June 2014
The objective of this patient registry is to collect data on the safety of Berinert® in normal clinical practice in the United States. The patient registry will be maintained for a period of at least 3 years. The duration of individual patient participation will vary and is determined by the frequency of hereditary angioedema (HAE) attacks and the patient's need for Berinert® treatment.

Condition Intervention
Includes: Hereditary Angioedema Biological: Berinert® (C1 Esterase Inhibitor)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Patient Registry for Berinert®, a C1-Esterase Inhibitor

Resource links provided by NLM:

Further study details as provided by CSL Behring:

Primary Outcome Measures:
  • Incidence of thrombotic and thrombo-embolic events [ Time Frame: Within 30 days of treatment with Berinert® ]
  • Occurrence of suspected viral transmission [ Time Frame: Duration of the study, at least 3 years ]
  • Use of concomitant medications and plasma products [ Time Frame: Duration of the study, at least 3 years ]

Enrollment: 318
Study Start Date: April 2010
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients requiring treatment with Berinert®
Biological: Berinert® (C1 Esterase Inhibitor)
Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
Other Names:
  • C1-INH
  • Berinert P
  • CE1145


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
An attempt will be made to prospectively identify patients and enroll them into this registry before treatment is required. In addition, retrospective chart/case review and data collection may be conducted.

Inclusion Criteria:

  • Any patient receiving CSL Behring's C1-esterase inhibitor
  • Written informed consent (may not be required for some retrospective chart review cases)

Exclusion Criteria:

  • Any patient participating in an HAE study using other C1-inhibitors than Berinert®
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01108848

  Hide Study Locations
United States, Arizona
United States, Arizona
Scottsdale, Arizona, United States, 85251
United States, California
United States, California
Granada Hills, California, United States, 91344
United States, California
Los Angeles, California, United States, 90095
United States, California
Redding, California, United States, 96003
United States, California
San Diego, California, United States, 92093
United States, Georgia
United States, Georgia
Atlanta, Georgia, United States, 30342
United States, Idaho
United States, Idaho
Idaho Falls, Idaho, United States, 83404
United States, Louisiana
United States, Louisiana
New Orleans, Louisiana, United States, 70118
United States, Maryland
United States, Maryland
Chevy Chase, Maryland, United States, 20815
United States, Maryland
Columbia, Maryland, United States, 21044
United States, Massachusetts
United States, Massachusetts
Boston, Massachusetts, United States, 02115
United States, Minnesota
United States, Minnesota
Plymouth, Minnesota, United States, 55446
United States, Missouri
United States, Missouri
Kansas City, Missouri, United States, 64108
United States, Missouri
St. Louis, Missouri, United States, 63110
United States, New Jersey
United States, New Jersey
Branchburg, New Jersey, United States, 08876
United States, New Jersey
Edison, New Jersey, United States, 88220
United States, New Jersey
Iselin, New Jersey, United States, 08830
United States, New Jersey
Ocean, New Jersey, United States, 07712
United States, New York
United States, New York
New York, New York, United States, 10029
United States, New York
North Syracuse, New York, United States, 13212
United States, North Carolina
United States, North Carolina
Durham, North Carolina, United States, 27710
United States, Ohio
United States, Ohio
Centerville, Ohio, United States, 45458
United States, Ohio
Cincinnati, Ohio, United States, 45267
United States, Oklahoma
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73131
United States, Oklahoma
Tulsa, Oklahoma, United States, 74133
United States, Oregon
United States, Oregon
Lake Oswego, Oregon, United States, 97035
United States, Pennsylvania
United States, Pennsylvania
Altoona, Pennsylvania, United States, 16601
United States, Pennsylvania
Hershey, Pennsylvania, United States, 17033
United States, Pennsylvania
Pittsburgh, Pennsylvania, United States, 15213
United States, South Carolina
United States, South Carolina
Columbia, South Carolina, United States, 29203
United States, South Dakota
United States, South Dakota
Rapid City, South Dakota, United States, 57702
United States, Texas
United States, Texas
Dallas, Texas, United States, 75231
United States, Washington
United States, Washington
Spokane, Washington, United States, 99204
United States, Washington
Tacoma, Washington, United States, 98405
Denmark, Odense C
Odense C, Denmark, 5000
Germany, Berlin
Berlin, Germany, 10117
Germany, Frankfurt
Frankfurt, Germany, 60596
Germany, Mainz
Mainz, Germany, 55101
Germany, München
München, Germany, 81675
Switzerland, Luzern 16
Luzern 16, Switzerland, CH-6000
Sponsors and Collaborators
CSL Behring
Chiltern International Inc.
Study Director: Global Clinical Program Director CSL Behring
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: CSL Behring Identifier: NCT01108848     History of Changes
Other Study ID Numbers: CE1145_5002
1500 ( Other Identifier: CSL Behring )
Study First Received: April 12, 2010
Last Updated: June 5, 2014

Keywords provided by CSL Behring:
C1-esterase Inhibitor
Hereditary angioedema
Acute HAE attack

Additional relevant MeSH terms:
Angioedemas, Hereditary
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Immune System Diseases
Genetic Diseases, Inborn
Complement C1s
Complement C1 Inhibitor Protein
Complement C1 Inactivator Proteins
Immunologic Factors
Physiological Effects of Drugs
Complement Inactivating Agents
Immunosuppressive Agents processed this record on September 20, 2017